Department of Internal Medicine, Dong-A University College of Medicine, 3-Ga Dongdaeshin-dong, Seo-gu, Busan 602-715, Republic of Korea.
Lung Cancer. 2010 Nov;70(2):188-94. doi: 10.1016/j.lungcan.2010.02.006. Epub 2010 Mar 12.
A dendritic cell vaccine has been developed as a novel strategy for generating antitumor immunity in the treatment of cancer. The purpose of this study was to assess the maximal tolerated dose, safety, and immunologic response of a new dendritic cell vaccine (DC-Vac) into which tumor lysate was loaded by electroporation and pulse in patients with advanced non-small cell lung cancer (NSCLC).
Fifteen patients with inoperable stage III or IV NSCLC were assigned to cohorts that received 3, 6, or 12 × 10(6) DC-Vac intradermally 3 times at 2 week intervals. We also evaluated immunologic and tumor responses.
The maximum dose of DC-Vac (12 × 10(6)) was shown to be safe. In 5 of 9 patients, the vaccine resulted in increased interferon (IFN)-γ production by CD8+ cells after exposure to tumor lysate. Additionally, there were mixed responses which do fulfill progressive disease definition but demonstrate some clinical benefit in two patients.
The administration of tumor lysate-loaded autologous dendritic cells by electroporation and pulse was non-toxic and induced immunologic responses to tumor antigens. The two mixed tumor responses which were achieved may represent a potential benefit of this new DC-Vac.
树突状细胞疫苗已被开发为一种治疗癌症的新策略，旨在产生抗肿瘤免疫。本研究旨在评估一种新的树突状细胞疫苗（DC-Vac）的最大耐受剂量、安全性和免疫反应，该疫苗通过电穿孔和脉冲加载肿瘤裂解物，用于治疗晚期非小细胞肺癌（NSCLC）患者。
15 名无法手术的 III 期或 IV 期 NSCLC 患者被分配到接受 3、6 或 12×10^6^ DC-Vac 皮内注射的队列，每 2 周 3 次，共 3 次。我们还评估了免疫和肿瘤反应。
显示 DC-Vac（12×10^6^）的最大剂量是安全的。在 9 名患者中的 5 名中，疫苗接种后，CD8+细胞对肿瘤裂解物产生的干扰素（IFN）-γ增加。此外，有混合反应，符合进展性疾病的定义，但在两名患者中表现出一定的临床获益。
电穿孔和脉冲加载自体树突状细胞的肿瘤裂解物给药无毒性，并诱导针对肿瘤抗原的免疫反应。两种混合肿瘤反应可能代表这种新的 DC-Vac 的潜在益处。
